New York, Oct. 13, 2022 (GLOBE NEWSWIRE) -- Reportlinker.com announces the release of the report "Global RNA Analysis / Transcriptomics Industry" - https://www.reportlinker.com/p06219553/?utm_source=GNW
Online interactive peer-to-peer collaborative bespoke updates
Access to our digital archives and MarketGlass Research Platform
Complimentary updates for one yearGlobal RNA Analysis / Transcriptomics Market to Reach $11.8 Billion by 2027
- In the changed post COVID-19 business landscape, the global market for RNA Analysis / Transcriptomics estimated at US$4.7 Billion in the year 2020, is projected to reach a revised size of US$11.8 Billion by 2027, growing at a CAGR of 14.1% over the analysis period 2020-2027. Reagents / Consumables, one of the segments analyzed in the report, is projected to record a 15.4% CAGR and reach US$5.9 Billion by the end of the analysis period. Taking into account the ongoing post pandemic recovery, growth in the Instruments segment is readjusted to a revised 12.5% CAGR for the next 7-year period.
- The U.S. Market is Estimated at $1.8 Billion, While China is Forecast to Grow at 15.6% CAGR
- The RNA Analysis / Transcriptomics market in the U.S. is estimated at US$1.8 Billion in the year 2020. China, the world`s second largest economy, is forecast to reach a projected market size of US$1 Billion by the year 2027 trailing a CAGR of 15.6% over the analysis period 2020 to 2027. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at 11.9% and 14.3% respectively over the 2020-2027 period. Within Europe, Germany is forecast to grow at approximately 13.8% CAGR.Services Segment to Record 14.2% CAGR
- In the global Services segment, USA, Canada, Japan, China and Europe will drive the 14.2% CAGR estimated for this segment. These regional markets accounting for a combined market size of US$744.8 Million in the year 2020 will reach a projected size of US$1.9 Billion by the close of the analysis period. China will remain among the fastest growing in this cluster of regional markets.
Select Competitors (Total 115 Featured)
Agilent Technologies, Inc.
Bio-Rad Laboratories, Inc.
CD Genomics
F. Hoffmann-La Roche Ltd.
GenXPro GmbH
Illumina, Inc.
LC Sciences
Merck KGaA
Qiagen N.V.
Sequentia Biotech SL
Thermo Fisher Scientific Inc.
Waters Corporation
Read the full report: https://www.reportlinker.com/p06219553/?utm_source=GNW
I. METHODOLOGY
II. EXECUTIVE SUMMARY
1. MARKET OVERVIEW
Impact of COVID-19 Pandemic and Looming Global Recession
2020 Marked as a Year of Disruption & Transformation
As the Race between the Virus & Vaccines Intensifies, Where is
the World Economy Headed?
Pandemic Impact on RNA Analysis/Transcriptomics Market
RNA-Oriented Projects Set to Increase
Competition
EXHIBIT 1: RNA Analysis / Transcriptomics - Global Key
Competitors Percentage Market Share in 2022 (E)
Competitive Market Presence - Strong/Active/Niche/Trivial for
44 Players Worldwide in 2022 (E)
What is RNA-Seq Technology?
A Prelude to Transcriptomics Technologies
Global Market Prospects & Outlook
PCR Emerges as the Leading Technology
Drug Discovery Segment Poised to Lead the Global Market
North America Emerges as the Major Regional Market
World Brands
Recent Market Activity
2. FOCUS ON SELECT PLAYERS
3. MARKET TRENDS & DRIVERS
Trend Towards Personalized Medicine Fuels Market Growth
EXHIBIT 2: Global Personalized Medicine Market: Revenues in US$
Million for the Years 2019, 2021, 2023 and 2025
EXHIBIT 3: World Personalized Medicine Market by Region/Country
(2021)
EXHIBIT 4: Drug Ineffectiveness for Select Therapeutic
Categories as a Percentage of Patient Population
EXHIBIT 5: Number of Available Personalized Medicines in the US
(2010-2020)
EXHIBIT 6: Personalized Medicines as % of New FDA Drug
Approvals for 2015-2021
Transcriptomics Assume Critical Importance amid Growing
Prevalence of Chronic Diseases
EXHIBIT 7: World Diabetes and Population Statistics (2021, 2030 &
2045)
EXHIBIT 8: World Diabetes Prevalence (2000-2045)
EXHIBIT 9: Fatalities by Heart Conditions: Estimated Percentage
Breakdown for Cardiovascular Disease, Ischemic Heart Disease,
Stroke, and Others
EXHIBIT 10: Global HIV Prevalence: Number of People Living with
AIDs (in Million) by Region as of June 2021
EXHIBIT 11: Burden of Neurological Diseases: Deaths Per 100,000
Population due to Neurological Conditions in Select Countries
Transcriptomics Applications in Disease and Diagnostic Profiling
Increasing PCR Applications in Biotechnology Sector
Progressive Growth of Omics Technologies: Opportunity for RNA
Analysis/ Transcriptomics Market
The Growing Role of Transcriptomics in Oncology
EXHIBIT 12: Global Cancer Incidence: Number of New Cancer Cases
in Million for the Years 2018, 2020, 2025, 2030, 2035 and 2040
EXHIBIT 13: Global Number of New Cancer Cases and Cancer-
related Deaths by Cancer Site for 2020
EXHIBIT 14: Number of New Cancer Cases and Deaths (in Million)
by Region for 2020
RNA Sequencing Critical for Cancer and Rare Diseases
Bulk-Tissue RNA Sequencing and Single-Cell RNA Sequencing for
Cardiovascular Research
Bulk RNA Sequencing
Single-Cell Sequencing
Spatial Transcriptomics
Single-Cell RNA-seq Technologies Witness Steady Growth
The Evolution of scRNA-seq
Growth of Long-Read Transcriptome Sequencing
scRNA-seq for Autoimmune Inflammatory Rheumatic Diseases
SPLiTseq Beneficial for Understanding Cause of Disease
Gene Expression Microarray Technology Gains Ground
Microfluidics-based Droplet Technologies Demonstrate Growth
inDrops Approach Exhibits Growth
Spatial Transcriptomics Market Witnesses Significant Growth
Spatial Transcriptomic Data Analysis
Next Generation Sequencing Offers Increased Accuracy for
Transcriptomics Activity
Single-cell NGS Witnesses Rapid Growth
RNA Sequencing Benefits Fuel Market Prospects
Blood Transcriptome Sequencing for Identifying Rare-Disease Genes
Rising Focus on Toxicogenomics: Potential for RNA Analysis/
Transcriptomics Markets
Growing R&D Spending in Pharma and Biotechnology Sectors
Presents Opportunities
EXHIBIT 15: Pharmaceutical R&D Spending Worldwide (USD Billion)
for 2015-2025
EXHIBIT 16: R&D Spending as % of Revenues in Select Leading
Pharmaceutical Companies (2020)
EXHIBIT 17: R&D Spending (in US$ Billion) of Select Leading
Biotechnology Companies for 2020
Technological Advancements & Innovations Fuel Market Growth
Sci-Plex - A New Technique to Profile Gene Expression within
Single Cells
Introduction of Oxford Nanopore?s Innovative Portable Sequencer
for Sequencing Long Reads and RNA Molecules Improves
Transcriptomic Analysis
RNA-Combine, a Toolkit for More Comprehensively Analyzing
Transcriptome Data
Aging Demographics Present Opportunities for Transcriptomics
Technologies
EXHIBIT 18: Global Aging Population Statistics for the 65+ Age
Group in Million by Geographic Region for the Years 2019,
2025, 2035 and 2050
EXHIBIT 19: Elderly Population (65+ Years) as a % of Total
Population by Developed, Less Developed and Least Developed
Regions: 2019 & 2030
Challenges Facing RNA/Transcriptomics Market
4. GLOBAL MARKET PERSPECTIVE
Table 1: World Recent Past, Current & Future Analysis for RNA
Analysis / Transcriptomics by Geographic Region - USA, Canada,
Japan, China, Europe, Asia-Pacific and Rest of World Markets -
Independent Analysis of Annual Revenues in US$ Thousand for
Years 2020 through 2027 and % CAGR
Table 2: World Historic Review for RNA Analysis /
Transcriptomics by Geographic Region - USA, Canada, Japan,
China, Europe, Asia-Pacific and Rest of World Markets -
Independent Analysis of Annual Revenues in US$ Thousand for
Years 2015 through 2019 and % CAGR
Table 3: World 12-Year Perspective for RNA Analysis /
Transcriptomics by Geographic Region - Percentage Breakdown of
Value Revenues for USA, Canada, Japan, China, Europe,
Asia-Pacific and Rest of World Markets for Years 2015, 2021 &
2027
Table 4: World Recent Past, Current & Future Analysis for
Reagents / Consumables by Geographic Region - USA, Canada,
Japan, China, Europe, Asia-Pacific and Rest of World Markets -
Independent Analysis of Annual Revenues in US$ Thousand for
Years 2020 through 2027 and % CAGR
Table 5: World Historic Review for Reagents / Consumables by
Geographic Region - USA, Canada, Japan, China, Europe,
Asia-Pacific and Rest of World Markets - Independent Analysis
of Annual Revenues in US$ Thousand for Years 2015 through 2019
and % CAGR
Table 6: World 12-Year Perspective for Reagents / Consumables
by Geographic Region - Percentage Breakdown of Value Revenues
for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of
World for Years 2015, 2021 & 2027
Table 7: World Recent Past, Current & Future Analysis for
Instruments by Geographic Region - USA, Canada, Japan, China,
Europe, Asia-Pacific and Rest of World Markets - Independent
Analysis of Annual Revenues in US$ Thousand for Years 2020
through 2027 and % CAGR
Table 8: World Historic Review for Instruments by Geographic
Region - USA, Canada, Japan, China, Europe, Asia-Pacific and
Rest of World Markets - Independent Analysis of Annual Revenues
in US$ Thousand for Years 2015 through 2019 and % CAGR
Table 9: World 12-Year Perspective for Instruments by
Geographic Region - Percentage Breakdown of Value Revenues for
USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of
World for Years 2015, 2021 & 2027
Table 10: World Recent Past, Current & Future Analysis for
Services by Geographic Region - USA, Canada, Japan, China,
Europe, Asia-Pacific and Rest of World Markets - Independent
Analysis of Annual Revenues in US$ Thousand for Years 2020
through 2027 and % CAGR
Table 11: World Historic Review for Services by Geographic
Region - USA, Canada, Japan, China, Europe, Asia-Pacific and
Rest of World Markets - Independent Analysis of Annual Revenues
in US$ Thousand for Years 2015 through 2019 and % CAGR
Table 12: World 12-Year Perspective for Services by Geographic
Region - Percentage Breakdown of Value Revenues for USA,
Canada, Japan, China, Europe, Asia-Pacific and Rest of World
for Years 2015, 2021 & 2027
Table 13: World Recent Past, Current & Future Analysis for
Software by Geographic Region - USA, Canada, Japan, China,
Europe, Asia-Pacific and Rest of World Markets - Independent
Analysis of Annual Revenues in US$ Thousand for Years 2020
through 2027 and % CAGR
Table 14: World Historic Review for Software by Geographic
Region - USA, Canada, Japan, China, Europe, Asia-Pacific and
Rest of World Markets - Independent Analysis of Annual Revenues
in US$ Thousand for Years 2015 through 2019 and % CAGR
Table 15: World 12-Year Perspective for Software by Geographic
Region - Percentage Breakdown of Value Revenues for USA,
Canada, Japan, China, Europe, Asia-Pacific and Rest of World
for Years 2015, 2021 & 2027
Table 16: World Recent Past, Current & Future Analysis for
Polymerase Chain Reaction by Geographic Region - USA, Canada,
Japan, China, Europe, Asia-Pacific and Rest of World Markets -
Independent Analysis of Annual Revenues in US$ Thousand for
Years 2020 through 2027 and % CAGR
Table 17: World Historic Review for Polymerase Chain Reaction
by Geographic Region - USA, Canada, Japan, China, Europe,
Asia-Pacific and Rest of World Markets - Independent Analysis
of Annual Revenues in US$ Thousand for Years 2015 through 2019
and % CAGR
Table 18: World 12-Year Perspective for Polymerase Chain
Reaction by Geographic Region - Percentage Breakdown of Value
Revenues for USA, Canada, Japan, China, Europe, Asia-Pacific
and Rest of World for Years 2015, 2021 & 2027
Table 19: World Recent Past, Current & Future Analysis for
Sequencing by Geographic Region - USA, Canada, Japan, China,
Europe, Asia-Pacific and Rest of World Markets - Independent
Analysis of Annual Revenues in US$ Thousand for Years 2020
through 2027 and % CAGR
Table 20: World Historic Review for Sequencing by Geographic
Region - USA, Canada, Japan, China, Europe, Asia-Pacific and
Rest of World Markets - Independent Analysis of Annual Revenues
in US$ Thousand for Years 2015 through 2019 and % CAGR
Table 21: World 12-Year Perspective for Sequencing by
Geographic Region - Percentage Breakdown of Value Revenues for
USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of
World for Years 2015, 2021 & 2027
Table 22: World Recent Past, Current & Future Analysis for
Microarrays by Geographic Region - USA, Canada, Japan, China,
Europe, Asia-Pacific and Rest of World Markets - Independent
Analysis of Annual Revenues in US$ Thousand for Years 2020
through 2027 and % CAGR
Table 23: World Historic Review for Microarrays by Geographic
Region - USA, Canada, Japan, China, Europe, Asia-Pacific and
Rest of World Markets - Independent Analysis of Annual Revenues
in US$ Thousand for Years 2015 through 2019 and % CAGR
Table 24: World 12-Year Perspective for Microarrays by
Geographic Region - Percentage Breakdown of Value Revenues for
USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of
World for Years 2015, 2021 & 2027
Table 25: World Recent Past, Current & Future Analysis for RNA
Interference by Geographic Region - USA, Canada, Japan, China,
Europe, Asia-Pacific and Rest of World Markets - Independent
Analysis of Annual Revenues in US$ Thousand for Years 2020
through 2027 and % CAGR
Table 26: World Historic Review for RNA Interference by
Geographic Region - USA, Canada, Japan, China, Europe,
Asia-Pacific and Rest of World Markets - Independent Analysis
of Annual Revenues in US$ Thousand for Years 2015 through 2019
and % CAGR
Table 27: World 12-Year Perspective for RNA Interference by
Geographic Region - Percentage Breakdown of Value Revenues for
USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of
World for Years 2015, 2021 & 2027
Table 28: World Recent Past, Current & Future Analysis for Drug
Discovery by Geographic Region - USA, Canada, Japan, China,
Europe, Asia-Pacific and Rest of World Markets - Independent
Analysis of Annual Revenues in US$ Thousand for Years 2020
through 2027 and % CAGR
Table 29: World Historic Review for Drug Discovery by
Geographic Region - USA, Canada, Japan, China, Europe,
Asia-Pacific and Rest of World Markets - Independent Analysis
of Annual Revenues in US$ Thousand for Years 2015 through 2019
and % CAGR
Table 30: World 12-Year Perspective for Drug Discovery by
Geographic Region - Percentage Breakdown of Value Revenues for
USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of
World for Years 2015, 2021 & 2027
Table 31: World Recent Past, Current & Future Analysis for
Toxicogenomics by Geographic Region - USA, Canada, Japan,
China, Europe, Asia-Pacific and Rest of World Markets -
Independent Analysis of Annual Revenues in US$ Thousand for
Years 2020 through 2027 and % CAGR
Table 32: World Historic Review for Toxicogenomics by
Geographic Region - USA, Canada, Japan, China, Europe,
Asia-Pacific and Rest of World Markets - Independent Analysis
of Annual Revenues in US$ Thousand for Years 2015 through 2019
and % CAGR
Table 33: World 12-Year Perspective for Toxicogenomics by
Geographic Region - Percentage Breakdown of Value Revenues for
USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of
World for Years 2015, 2021 & 2027
Table 34: World Recent Past, Current & Future Analysis for
Clinical Diagnostics by Geographic Region - USA, Canada, Japan,
China, Europe, Asia-Pacific and Rest of World Markets -
Independent Analysis of Annual Revenues in US$ Thousand for
Years 2020 through 2027 and % CAGR
Table 35: World Historic Review for Clinical Diagnostics by
Geographic Region - USA, Canada, Japan, China, Europe,
Asia-Pacific and Rest of World Markets - Independent Analysis
of Annual Revenues in US$ Thousand for Years 2015 through 2019
and % CAGR
Table 36: World 12-Year Perspective for Clinical Diagnostics by
Geographic Region - Percentage Breakdown of Value Revenues for
USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of
World for Years 2015, 2021 & 2027
Table 37: World Recent Past, Current & Future Analysis for
Comparative Transcriptomics by Geographic Region - USA, Canada,
Japan, China, Europe, Asia-Pacific and Rest of World Markets -
Independent Analysis of Annual Revenues in US$ Thousand for
Years 2020 through 2027 and % CAGR
Table 38: World Historic Review for Comparative Transcriptomics
by Geographic Region - USA, Canada, Japan, China, Europe,
Asia-Pacific and Rest of World Markets - Independent Analysis
of Annual Revenues in US$ Thousand for Years 2015 through 2019
and % CAGR
Table 39: World 12-Year Perspective for Comparative
Transcriptomics by Geographic Region - Percentage Breakdown of
Value Revenues for USA, Canada, Japan, China, Europe,
Asia-Pacific and Rest of World for Years 2015, 2021 & 2027
III. MARKET ANALYSIS
UNITED STATES
RNA Analysis / Transcriptomics Market Presence - Strong/Active/
Niche/Trivial - Key Competitors in the United States for 2022
(E)
Market Analytics
Table 40: USA Recent Past, Current & Future Analysis for RNA
Analysis / Transcriptomics by Product - Reagents / Consumables,
Instruments, Services and Software - Independent Analysis of
Annual Revenues in US$ Thousand for the Years 2020 through 2027
and % CAGR
Table 41: USA Historic Review for RNA Analysis /
Transcriptomics by Product - Reagents / Consumables,
Instruments, Services and Software Markets - Independent
Analysis of Annual Revenues in US$ Thousand for Years 2015
through 2019 and % CAGR
Table 42: USA 12-Year Perspective for RNA Analysis /
Transcriptomics by Product - Percentage Breakdown of Value
Revenues for Reagents / Consumables, Instruments, Services and
Software for the Years 2015, 2021 & 2027
Table 43: USA Recent Past, Current & Future Analysis for RNA
Analysis / Transcriptomics by Technology - Polymerase Chain
Reaction, Sequencing, Microarrays and RNA Interference -
Independent Analysis of Annual Revenues in US$ Thousand for the
Years 2020 through 2027 and % CAGR
Table 44: USA Historic Review for RNA Analysis /
Transcriptomics by Technology - Polymerase Chain Reaction,
Sequencing, Microarrays and RNA Interference Markets -
Independent Analysis of Annual Revenues in US$ Thousand for
Years 2015 through 2019 and % CAGR
Table 45: USA 12-Year Perspective for RNA Analysis /
Transcriptomics by Technology - Percentage Breakdown of Value
Revenues for Polymerase Chain Reaction, Sequencing, Microarrays
and RNA Interference for the Years 2015, 2021 & 2027
Table 46: USA Recent Past, Current & Future Analysis for RNA
Analysis / Transcriptomics by Application - Drug Discovery,
Toxicogenomics, Clinical Diagnostics and Comparative
Transcriptomics - Independent Analysis of Annual Revenues in
US$ Thousand for the Years 2020 through 2027 and % CAGR
Table 47: USA Historic Review for RNA Analysis /
Transcriptomics by Application - Drug Discovery,
Toxicogenomics, Clinical Diagnostics and Comparative
Transcriptomics Markets - Independent Analysis of Annual
Revenues in US$ Thousand for Years 2015 through 2019 and % CAGR
Table 48: USA 12-Year Perspective for RNA Analysis /
Transcriptomics by Application - Percentage Breakdown of Value
Revenues for Drug Discovery, Toxicogenomics, Clinical
Diagnostics and Comparative Transcriptomics for the Years 2015,
2021 & 2027
CANADA
Table 49: Canada Recent Past, Current & Future Analysis for RNA
Analysis / Transcriptomics by Product - Reagents / Consumables,
Instruments, Services and Software - Independent Analysis of
Annual Revenues in US$ Thousand for the Years 2020 through 2027
and % CAGR
Table 50: Canada Historic Review for RNA Analysis /
Transcriptomics by Product - Reagents / Consumables,
Instruments, Services and Software Markets - Independent
Analysis of Annual Revenues in US$ Thousand for Years 2015
through 2019 and % CAGR
Table 51: Canada 12-Year Perspective for RNA Analysis /
Transcriptomics by Product - Percentage Breakdown of Value
Revenues for Reagents / Consumables, Instruments, Services and
Software for the Years 2015, 2021 & 2027
Table 52: Canada Recent Past, Current & Future Analysis for RNA
Analysis / Transcriptomics by Technology - Polymerase Chain
Reaction, Sequencing, Microarrays and RNA Interference -
Independent Analysis of Annual Revenues in US$ Thousand for the
Years 2020 through 2027 and % CAGR
Table 53: Canada Historic Review for RNA Analysis /
Transcriptomics by Technology - Polymerase Chain Reaction,
Sequencing, Microarrays and RNA Interference Markets -
Independent Analysis of Annual Revenues in US$ Thousand for
Years 2015 through 2019 and % CAGR
Table 54: Canada 12-Year Perspective for RNA Analysis /
Transcriptomics by Technology - Percentage Breakdown of Value
Revenues for Polymerase Chain Reaction, Sequencing, Microarrays
and RNA Interference for the Years 2015, 2021 & 2027
Table 55: Canada Recent Past, Current & Future Analysis for RNA
Analysis / Transcriptomics by Application - Drug Discovery,
Toxicogenomics, Clinical Diagnostics and Comparative
Transcriptomics - Independent Analysis of Annual Revenues in
US$ Thousand for the Years 2020 through 2027 and % CAGR
Table 56: Canada Historic Review for RNA Analysis /
Transcriptomics by Application - Drug Discovery,
Toxicogenomics, Clinical Diagnostics and Comparative
Transcriptomics Markets - Independent Analysis of Annual
Revenues in US$ Thousand for Years 2015 through 2019 and % CAGR
Table 57: Canada 12-Year Perspective for RNA Analysis /
Transcriptomics by Application - Percentage Breakdown of Value
Revenues for Drug Discovery, Toxicogenomics, Clinical
Diagnostics and Comparative Transcriptomics for the Years 2015,
2021 & 2027
JAPAN
Table 58: Japan Recent Past, Current & Future Analysis for RNA
Analysis / Transcriptomics by Product - Reagents / Consumables,
Instruments, Services and Software - Independent Analysis of
Annual Revenues in US$ Thousand for the Years 2020 through 2027
and % CAGR
Table 59: Japan Historic Review for RNA Analysis /
Transcriptomics by Product - Reagents / Consumables,
Instruments, Services and Software Markets - Independent
Analysis of Annual Revenues in US$ Thousand for Years 2015
through 2019 and % CAGR
Table 60: Japan 12-Year Perspective for RNA Analysis /
Transcriptomics by Product - Percentage Breakdown of Value
Revenues for Reagents / Consumables, Instruments, Services and
Software for the Years 2015, 2021 & 2027
Table 61: Japan Recent Past, Current & Future Analysis for RNA
Analysis / Transcriptomics by Technology - Polymerase Chain
Reaction, Sequencing, Microarrays and RNA Interference -
Independent Analysis of Annual Revenues in US$ Thousand for the
Years 2020 through 2027 and % CAGR
Table 62: Japan Historic Review for RNA Analysis /
Transcriptomics by Technology - Polymerase Chain Reaction,
Sequencing, Microarrays and RNA Interference Markets -
Independent Analysis of Annual Revenues in US$ Thousand for
Years 2015 through 2019 and % CAGR
Table 63: Japan 12-Year Perspective for RNA Analysis /
Transcriptomics by Technology - Percentage Breakdown of Value
Revenues for Polymerase Chain Reaction, Sequencing, Microarrays
and RNA Interference for the Years 2015, 2021 & 2027
Table 64: Japan Recent Past, Current & Future Analysis for RNA
Analysis / Transcriptomics by Application - Drug Discovery,
Toxicogenomics, Clinical Diagnostics and Comparative
Transcriptomics - Independent Analysis of Annual Revenues in
US$ Thousand for the Years 2020 through 2027 and % CAGR
Table 65: Japan Historic Review for RNA Analysis /
Transcriptomics by Application - Drug Discovery,
Toxicogenomics, Clinical Diagnostics and Comparative
Transcriptomics Markets - Independent Analysis of Annual
Revenues in US$ Thousand for Years 2015 through 2019 and % CAGR
Table 66: Japan 12-Year Perspective for RNA Analysis /
Transcriptomics by Application - Percentage Breakdown of Value
Revenues for Drug Discovery, Toxicogenomics, Clinical
Diagnostics and Comparative Transcriptomics for the Years 2015,
2021 & 2027
CHINA
RNA Analysis / Transcriptomics Market Presence - Strong/Active/
Niche/Trivial - Key Competitors in China for 2022 (E)
Market Analytics
Table 67: China Recent Past, Current & Future Analysis for RNA
Analysis / Transcriptomics by Product - Reagents / Consumables,
Instruments, Services and Software - Independent Analysis of
Annual Revenues in US$ Thousand for the Years 2020 through 2027
and % CAGR
Table 68: China Historic Review for RNA Analysis /
Transcriptomics by Product - Reagents / Consumables,
Instruments, Services and Software Markets - Independent
Analysis of Annual Revenues in US$ Thousand for Years 2015
through 2019 and % CAGR
Table 69: China 12-Year Perspective for RNA Analysis /
Transcriptomics by Product - Percentage Breakdown of Value
Revenues for Reagents / Consumables, Instruments, Services and
Software for the Years 2015, 2021 & 2027
Table 70: China Recent Past, Current & Future Analysis for RNA
Analysis / Transcriptomics by Technology - Polymerase Chain
Reaction, Sequencing, Microarrays and RNA Interference -
Independent Analysis of Annual Revenues in US$ Thousand for the
Years 2020 through 2027 and % CAGR
Table 71: China Historic Review for RNA Analysis /
Transcriptomics by Technology - Polymerase Chain Reaction,
Sequencing, Microarrays and RNA Interference Markets -
Independent Analysis of Annual Revenues in US$ Thousand for
Years 2015 through 2019 and % CAGR
Table 72: China 12-Year Perspective for RNA Analysis /
Transcriptomics by Technology - Percentage Breakdown of Value
Revenues for Polymerase Chain Reaction, Sequencing, Microarrays
and RNA Interference for the Years 2015, 2021 & 2027
Table 73: China Recent Past, Current & Future Analysis for RNA
Analysis / Transcriptomics by Application - Drug Discovery,
Toxicogenomics, Clinical Diagnostics and Comparative
Transcriptomics - Independent Analysis of Annual Revenues in
US$ Thousand for the Years 2020 through 2027 and % CAGR
Table 74: China Historic Review for RNA Analysis /
Transcriptomics by Application - Drug Discovery,
Toxicogenomics, Clinical Diagnostics and Comparative
Transcriptomics Markets - Independent Analysis of Annual
Revenues in US$ Thousand for Years 2015 through 2019 and % CAGR
Table 75: China 12-Year Perspective for RNA Analysis /
Transcriptomics by Application - Percentage Breakdown of Value
Revenues for Drug Discovery, Toxicogenomics, Clinical
Diagnostics and Comparative Transcriptomics for the Years 2015,
2021 & 2027
EUROPE
RNA Analysis / Transcriptomics Market Presence - Strong/Active/
Niche/Trivial - Key Competitors in Europe for 2022 (E)
Market Analytics
Table 76: Europe Recent Past, Current & Future Analysis for RNA
Analysis / Transcriptomics by Geographic Region - France,
Germany, Italy, UK and Rest of Europe Markets - Independent
Analysis of Annual Revenues in US$ Thousand for Years 2020
through 2027 and % CAGR
Table 77: Europe Historic Review for RNA Analysis /
Transcriptomics by Geographic Region - France, Germany, Italy,
UK and Rest of Europe Markets - Independent Analysis of Annual
Revenues in US$ Thousand for Years 2015 through 2019 and % CAGR
Table 78: Europe 12-Year Perspective for RNA Analysis /
Transcriptomics by Geographic Region - Percentage Breakdown of
Value Revenues for France, Germany, Italy, UK and Rest of
Europe Markets for Years 2015, 2021 & 2027
Table 79: Europe Recent Past, Current & Future Analysis for RNA
Analysis / Transcriptomics by Product - Reagents / Consumables,
Instruments, Services and Software - Independent Analysis of
Annual Revenues in US$ Thousand for the Years 2020 through 2027
and % CAGR
Table 80: Europe Historic Review for RNA Analysis /
Transcriptomics by Product - Reagents / Consumables,
Instruments, Services and Software Markets - Independent
Analysis of Annual Revenues in US$ Thousand for Years 2015
through 2019 and % CAGR
Table 81: Europe 12-Year Perspective for RNA Analysis /
Transcriptomics by Product - Percentage Breakdown of Value
Revenues for Reagents / Consumables, Instruments, Services and
Software for the Years 2015, 2021 & 2027
Table 82: Europe Recent Past, Current & Future Analysis for RNA
Analysis / Transcriptomics by Technology - Polymerase Chain
Reaction, Sequencing, Microarrays and RNA Interference -
Independent Analysis of Annual Revenues in US$ Thousand for the
Years 2020 through 2027 and % CAGR
Table 83: Europe Historic Review for RNA Analysis /
Transcriptomics by Technology - Polymerase Chain Reaction,
Sequencing, Microarrays and RNA Interference Markets -
Independent Analysis of Annual Revenues in US$ Thousand for
Years 2015 through 2019 and % CAGR
Table 84: Europe 12-Year Perspective for RNA Analysis /
Transcriptomics by Technology - Percentage Breakdown of Value
Revenues for Polymerase Chain Reaction, Sequencing, Microarrays
and RNA Interference for the Years 2015, 2021 & 2027
Table 85: Europe Recent Past, Current & Future Analysis for RNA
Analysis / Transcriptomics by Application - Drug Discovery,
Toxicogenomics, Clinical Diagnostics and Comparative
Transcriptomics - Independent Analysis of Annual Revenues in
US$ Thousand for the Years 2020 through 2027 and % CAGR
Table 86: Europe Historic Review for RNA Analysis /
Transcriptomics by Application - Drug Discovery,
Toxicogenomics, Clinical Diagnostics and Comparative
Transcriptomics Markets - Independent Analysis of Annual
Revenues in US$ Thousand for Years 2015 through 2019 and % CAGR
Table 87: Europe 12-Year Perspective for RNA Analysis /
Transcriptomics by Application - Percentage Breakdown of Value
Revenues for Drug Discovery, Toxicogenomics, Clinical
Diagnostics and Comparative Transcriptomics for the Years 2015,
2021 & 2027
FRANCE
Table 88: France Recent Past, Current & Future Analysis for RNA
Analysis / Transcriptomics by Product - Reagents / Consumables,
Instruments, Services and Software - Independent Analysis of
Annual Revenues in US$ Thousand for the Years 2020 through 2027
and % CAGR
Table 89: France Historic Review for RNA Analysis /
Transcriptomics by Product - Reagents / Consumables,
Instruments, Services and Software Markets - Independent
Analysis of Annual Revenues in US$ Thousand for Years 2015
through 2019 and % CAGR
Table 90: France 12-Year Perspective for RNA Analysis /
Transcriptomics by Product - Percentage Breakdown of Value
Revenues for Reagents / Consumables, Instruments, Services and
Software for the Years 2015, 2021 & 2027
Table 91: France Recent Past, Current & Future Analysis for RNA
Analysis / Transcriptomics by Technology - Polymerase Chain
Reaction, Sequencing, Microarrays and RNA Interference -
Independent Analysis of Annual Revenues in US$ Thousand for the
Years 2020 through 2027 and % CAGR
Table 92: France Historic Review for RNA Analysis /
Transcriptomics by Technology - Polymerase Chain Reaction,
Sequencing, Microarrays and RNA Interference Markets -
Independent Analysis of Annual Revenues in US$ Thousand for
Years 2015 through 2019 and % CAGR
Table 93: France 12-Year Perspective for RNA Analysis /
Transcriptomics by Technology - Percentage Breakdown of Value
Revenues for Polymerase Chain Reaction, Sequencing, Microarrays
and RNA Interference for the Years 2015, 2021 & 2027
Table 94: France Recent Past, Current & Future Analysis for RNA
Analysis / Transcriptomics by Application - Drug Discovery,
Toxicogenomics, Clinical Diagnostics and Comparative
Transcriptomics - Independent Analysis of Annual Revenues in
US$ Thousand for the Years 2020 through 2027 and % CAGR
Table 95: France Historic Review for RNA Analysis /
Transcriptomics by Application - Drug Discovery,
Toxicogenomics, Clinical Diagnostics and Comparative
Transcriptomics Markets - Independent Analysis of Annual
Revenues in US$ Thousand for Years 2015 through 2019 and % CAGR
Table 96: France 12-Year Perspective for RNA Analysis /
Transcriptomics by Application - Percentage Breakdown of Value
Revenues for Drug Discovery, Toxicogenomics, Clinical
Diagnostics and Comparative Transcriptomics for the Years 2015,
2021 & 2027
GERMANY
Table 97: Germany Recent Past, Current & Future Analysis for
RNA Analysis / Transcriptomics by Product - Reagents /
Consumables, Instruments, Services and Software - Independent
Analysis of Annual Revenues in US$ Thousand for the Years 2020
through 2027 and % CAGR
Table 98: Germany Historic Review for RNA Analysis /
Transcriptomics by Product - Reagents / Consumables,
Instruments, Services and Software Markets - Independent
Analysis of Annual Revenues in US$ Thousand for Years 2015
through 2019 and % CAGR
Table 99: Germany 12-Year Perspective for RNA Analysis /
Transcriptomics by Product - Percentage Breakdown of Value
Revenues for Reagents / Consumables, Instruments, Services and
Software for the Years 2015, 2021 & 2027
Table 100: Germany Recent Past, Current & Future Analysis for
RNA Analysis / Transcriptomics by Technology - Polymerase Chain
Reaction, Sequencing, Microarrays and RNA Interference -
Independent Analysis of Annual Revenues in US$ Thousand for the
Years 2020 through 2027 and % CAGR
Table 101: Germany Historic Review for RNA Analysis /
Transcriptomics by Technology - Polymerase Chain Reaction,
Sequencing, Microarrays and RNA Interference Markets -
Independent Analysis of Annual Revenues in US$ Thousand for
Years 2015 through 2019 and % CAGR
Table 102: Germany 12-Year Perspective for RNA Analysis /
Transcriptomics by Technology - Percentage Breakdown of Value
Revenues for Polymerase Chain Reaction, Sequencing, Microarrays
and RNA Interference for the Years 2015, 2021 & 2027
Table 103: Germany Recent Past, Current & Future Analysis for
RNA Analysis / Transcriptomics by Application - Drug Discovery,
Toxicogenomics, Clinical Diagnostics and Comparative
Transcriptomics - Independent Analysis of Annual Revenues in
US$ Thousand for the Years 2020 through 2027 and % CAGR
Table 104: Germany Historic Review for RNA Analysis /
Transcriptomics by Application - Drug Discovery,
Toxicogenomics, Clinical Diagnostics and Comparative
Transcriptomics Markets - Independent Analysis of Annual
Revenues in US$ Thousand for Years 2015 through 2019 and % CAGR
Table 105: Germany 12-Year Perspective for RNA Analysis /
Please contact our Customer Support Center to get the complete Table of Contents
Read the full report: https://www.reportlinker.com/p06219553/?utm_source=GNW
About Reportlinker
ReportLinker is an award-winning market research solution. Reportlinker finds and organizes the latest industry data so you get all the market research you need - instantly, in one place.
__________________________
